Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for ...

Metastases drive most cancer-related mortality. So, identifying mutations that are driving cancer growth and that are also present among all metastases of a cancer may be important in disease ...

GATA6 expression with CA19-9 levels as biomarkers in resectable pancreatic adenocarcinoma treated with neoadjuvant modified FOLFIRINOX in the NeoPancONE trial. This is an ASCO Meeting Abstract from ...

In this study, researchers aimed to characterize the mutational landscape of the tumors of domestic cats to determine whether similarities to humans could translate to the clinic.

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation ...

Please provide your email address to receive an email when new articles are posted on . Patients with myelofibrosis who cleared their mutations 30 days following stem cell transplantation experienced ...

The updated ASCO living guideline for stage IV driver mutation–negative NSCLC does not offer a single, simple answer, and ...

Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.

Clearance of driver mutations at day 30 after transplantation was associated with a reduced risk of relapse and better survival among patients with myelofibrosis, a German study showed. Disease-free ...

Experts share insights on the use chemotherapy and immunotherapy in driver-negative patients, along with the use of PD-L1 inhibitors. Joshua Sabari, MD: Yeah, I couldn’t agree more. I do the exact ...